|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
PSA, Total
Test Code5363
CPT Codes
84153
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Instructions
Do not collect specimen after a transrectal biopsy, results may be falsely elevated
Transport Container
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 28 days
Refrigerated: 14 days
Frozen: 28 days
Methodology
Immunoassay (IA)
Setup Schedule
Set up: Daily; Report available: Next day
Limitations
Based on solid evidence, screening with PSA and/or DRE detects some prostate cancers that would never have caused important clinical problems. Current prostate cancer treatments, including radical prostatectomy and radiation therapy, result in permanent side effects in many men. The most common of these side effects are erectile dystunction and urinary incontinence. Whatever the screening modality, the screening process itself can lead to adverse psychological effects in men who have a prostate biopsy but do not have identified prostate cancer. Prostatic biopsies are associated with complications, including fever, pain, hematospermia/hematuria, positive urine cultures, and rarely sepsis. Lower PSA levels are associated with obesity.
Reference Range
| Male | ≤4.00 ng/mL |
| Female | Not established |
Clinical Significance
Elevated serum PSA concentrations have been reported in men with prostate cancer, benign prostatic hypertrophy, and inflammatory conditions of the prostate.
